$OMED Recent Headlines OncoMed, Celge
Post# of 5325
Posted On: 12/03/2013 3:45:53 PM
$OMED Recent Headlines
OncoMed, Celgene Strike Cancer Drug Development Deal
10:06 a.m. Today10:06 a.m. Dec. 3, 2013
- Investors Business Daily
Why OncoMed (OMED) Shares Flew Sky High
9:46 a.m. Today9:46 a.m. Dec. 3, 2013
- TheStreet.com
OncoMed soars on demcizumab deal with Celgene
8:02 a.m. Today8:02 a.m. Dec. 3, 2013
- Seeking Alpha
10-Q: ONCOMED PHARMACEUTICALS INC
4:07 p.m. Nov. 13, 2013
- Edgar Online - (EDG = 10Q, 10K)
Jim Cramer: Sell Twitter, Buy Humana, and 3 More Stock Picks
9:48 a.m. Nov. 8, 2013
- Wall St. Cheat Sheet
Cramer's Lightning Round - Halcon Needs To Get It Together (11/7/13)
6:24 a.m. Nov. 8, 2013
- Seeking Alpha
'Mad Money' Lightning Round: I'm Buying Home Depot
6:00 a.m. Nov. 8, 2013
- TheStreet.com
Jim Cramer's 'Mad Money' Recap: Take the Money and Run
8:21 p.m. Nov. 7, 2013
- TheStreet.com
SA Pro: Top Long And Short Ideas, Tuesday October 22
6:30 a.m. Oct. 23, 2013
- Seeking Alpha
Wall Street Breakfast: Must-Know News
5:33 a.m. Oct. 23, 2013
- Seeking Alpha
OncoMed's Cancer Stem Cell Therapies Could Provide Outsized Gains For Investors
11:15 a.m. Oct. 22, 2013
- Seeking Alpha
Optimistic For OncoMed's Future
4:14 p.m. Sept. 25, 2013
- Seeking Alpha
Pipeline Progress at OncoMed - Analyst Blog
10:10 a.m. Sept. 20, 2013
- Zacks.com
10-Q: ONCOMED PHARMACEUTICALS INC
5:33 a.m. Sept. 3, 2013
- Edgar Online - (EDG = 10Q, 10K)
Patent for OncoMed's Vantictumab - Analyst Blog
4:00 p.m. Aug. 26, 2013
- Zacks.com
OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
6:33 a.m. Aug. 22, 2013
- benzinga.com
Cramer's Mad Money - Where Is Natural Gas Going? (8/15/13)
5:16 a.m. Aug. 16, 2013
- Seeking Alpha
UPDATE: Jefferies Initiates OncoMed Pharmaceuticals at Buy on Market Leader Position
8:32 a.m. Aug. 12, 2013
- benzinga.com
UPDATE: Piper Jaffray Initiates OncoMed Pharmaceuticals at Overweight on Emerging Cancer Antibody Play
6:20 a.m. Aug. 12, 2013
- benzinga.com
Oncomed: High Opening Day Returns For This BIotech Public Offering
4:20 p.m. July 19, 2013
- Seeking Alpha
Bullish Trend Analysis: Tesla Motors Inc, XOMA Corp, Keryx Biopharmaceuticals, Oncomed Pharmaceuticals
9:01 a.m. Today9:01 a.m. Dec. 3, 2013
- ACCESSWIRE
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
7:30 a.m. Today7:30 a.m. Dec. 3, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
5:12 p.m. Nov. 27, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
8:30 a.m. Nov. 15, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Announces Third Quarter 2013 Financial Results
8:30 a.m. Nov. 12, 2013
- GlobeNewswire
OMP-54F28 (Fzd8-Fc) Program Reaches Dose Escalation Milestone in Phase 1a Clinical Trial; Triggers $15 Million Payment From Bayer Pharma AG
8:30 a.m. Nov. 5, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Paclitaxel in Breast Cancer
7:30 a.m. Oct. 29, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
11:30 a.m. Oct. 21, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
11:30 a.m. Oct. 20, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Appoints Michael Wyzga to Board of Directors
7:31 a.m. Oct. 17, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics in Five Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
7:30 a.m. Oct. 14, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Receives First U.S. Patent on MAbTrap(TM) Antibody Display Technology
7:31 a.m. Oct. 9, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at 12th Annual BIO Investor Forum
3:15 p.m. Oct. 3, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013
2:31 a.m. Sept. 29, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Granted Additional Broad Anti-RSPO Antibody Patent in U.S.
7:30 a.m. Sept. 25, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013 (ECC 2013)
7:30 a.m. Sept. 23, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
7:30 a.m. Sept. 20, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer
7:30 a.m. Sept. 19, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Announces Second Quarter 2013 Financial Results
7:30 a.m. Sept. 3, 2013
- GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on CGIX, ESPR, OMED and STML
7:41 a.m. Aug. 26, 2013
- ACCESSWIRE
OncoMed, Celgene Strike Cancer Drug Development Deal
10:06 a.m. Today10:06 a.m. Dec. 3, 2013
- Investors Business Daily
Why OncoMed (OMED) Shares Flew Sky High
9:46 a.m. Today9:46 a.m. Dec. 3, 2013
- TheStreet.com
OncoMed soars on demcizumab deal with Celgene
8:02 a.m. Today8:02 a.m. Dec. 3, 2013
- Seeking Alpha
10-Q: ONCOMED PHARMACEUTICALS INC
4:07 p.m. Nov. 13, 2013
- Edgar Online - (EDG = 10Q, 10K)
Jim Cramer: Sell Twitter, Buy Humana, and 3 More Stock Picks
9:48 a.m. Nov. 8, 2013
- Wall St. Cheat Sheet
Cramer's Lightning Round - Halcon Needs To Get It Together (11/7/13)
6:24 a.m. Nov. 8, 2013
- Seeking Alpha
'Mad Money' Lightning Round: I'm Buying Home Depot
6:00 a.m. Nov. 8, 2013
- TheStreet.com
Jim Cramer's 'Mad Money' Recap: Take the Money and Run
8:21 p.m. Nov. 7, 2013
- TheStreet.com
SA Pro: Top Long And Short Ideas, Tuesday October 22
6:30 a.m. Oct. 23, 2013
- Seeking Alpha
Wall Street Breakfast: Must-Know News
5:33 a.m. Oct. 23, 2013
- Seeking Alpha
OncoMed's Cancer Stem Cell Therapies Could Provide Outsized Gains For Investors
11:15 a.m. Oct. 22, 2013
- Seeking Alpha
Optimistic For OncoMed's Future
4:14 p.m. Sept. 25, 2013
- Seeking Alpha
Pipeline Progress at OncoMed - Analyst Blog
10:10 a.m. Sept. 20, 2013
- Zacks.com
10-Q: ONCOMED PHARMACEUTICALS INC
5:33 a.m. Sept. 3, 2013
- Edgar Online - (EDG = 10Q, 10K)
Patent for OncoMed's Vantictumab - Analyst Blog
4:00 p.m. Aug. 26, 2013
- Zacks.com
OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)
6:33 a.m. Aug. 22, 2013
- benzinga.com
Cramer's Mad Money - Where Is Natural Gas Going? (8/15/13)
5:16 a.m. Aug. 16, 2013
- Seeking Alpha
UPDATE: Jefferies Initiates OncoMed Pharmaceuticals at Buy on Market Leader Position
8:32 a.m. Aug. 12, 2013
- benzinga.com
UPDATE: Piper Jaffray Initiates OncoMed Pharmaceuticals at Overweight on Emerging Cancer Antibody Play
6:20 a.m. Aug. 12, 2013
- benzinga.com
Oncomed: High Opening Day Returns For This BIotech Public Offering
4:20 p.m. July 19, 2013
- Seeking Alpha
Bullish Trend Analysis: Tesla Motors Inc, XOMA Corp, Keryx Biopharmaceuticals, Oncomed Pharmaceuticals
9:01 a.m. Today9:01 a.m. Dec. 3, 2013
- ACCESSWIRE
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients
7:30 a.m. Today7:30 a.m. Dec. 3, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
5:12 p.m. Nov. 27, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates Second Phase 1b Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
8:30 a.m. Nov. 15, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Announces Third Quarter 2013 Financial Results
8:30 a.m. Nov. 12, 2013
- GlobeNewswire
OMP-54F28 (Fzd8-Fc) Program Reaches Dose Escalation Milestone in Phase 1a Clinical Trial; Triggers $15 Million Payment From Bayer Pharma AG
8:30 a.m. Nov. 5, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates First Phase 1b Clinical Trial of First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) With Paclitaxel in Breast Cancer
7:30 a.m. Oct. 29, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
11:30 a.m. Oct. 21, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
11:30 a.m. Oct. 20, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Appoints Michael Wyzga to Board of Directors
7:31 a.m. Oct. 17, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (anti-CSC) Therapeutics in Five Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 19-23, 2013
7:30 a.m. Oct. 14, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Receives First U.S. Patent on MAbTrap(TM) Antibody Display Technology
7:31 a.m. Oct. 9, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at 12th Annual BIO Investor Forum
3:15 p.m. Oct. 3, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013
2:31 a.m. Sept. 29, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Granted Additional Broad Anti-RSPO Antibody Patent in U.S.
7:30 a.m. Sept. 25, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013 (ECC 2013)
7:30 a.m. Sept. 23, 2013
- GlobeNewswire
OncoMed Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
7:30 a.m. Sept. 20, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer
7:30 a.m. Sept. 19, 2013
- GlobeNewswire
OncoMed Pharmaceuticals Announces Second Quarter 2013 Financial Results
7:30 a.m. Sept. 3, 2013
- GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on CGIX, ESPR, OMED and STML
7:41 a.m. Aug. 26, 2013
- ACCESSWIRE
(0)
(0)Scroll down for more posts ▼